Maxim Group Analysts Give Juno Therapeutics (JUNO) a $56.00 Price Target

Maxim Group set a $56.00 price target on Juno Therapeutics (NASDAQ:JUNO) in a research report released on Wednesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

“The American Society of Hematology (ASH) is now over, and while we saw bluebird’s (BLUE – $190.95 – Hold) valuation rise to over $9B on strong data in CAR-T and gene therapy, Juno’s valuation has seen a retracement from its pre- ASH peak of $7B, to $5B on what is incremental data for lead CAR candidate JCAR017.”,” Maxim Group’s analyst commented.

Several other equities research analysts have also recently issued reports on JUNO. BTIG Research upgraded Juno Therapeutics from a sell rating to a neutral rating in a report on Monday, August 28th. Zacks Investment Research cut Juno Therapeutics from a hold rating to a sell rating in a report on Monday, August 28th. Wedbush raised shares of Juno Therapeutics from a neutral rating to an outperform rating and set a $42.00 target price on the stock in a research note on Tuesday, August 29th. Raymond James Financial raised shares of Juno Therapeutics from a market perform rating to an outperform rating and set a $45.00 target price on the stock in a research note on Tuesday, August 29th. Finally, ValuEngine raised shares of Juno Therapeutics from a sell rating to a hold rating in a research note on Tuesday, August 29th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the stock. Juno Therapeutics presently has an average rating of Hold and a consensus price target of $45.48.

Juno Therapeutics (NASDAQ JUNO) traded up $0.51 during mid-day trading on Wednesday, reaching $44.68. The company had a trading volume of 4,478,187 shares, compared to its average volume of 2,322,816. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.77 and a current ratio of 4.77. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $63.45.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The company had revenue of $44.80 million for the quarter, compared to analysts’ expectations of $18.12 million. During the same period in the previous year, the firm posted ($0.57) EPS. Juno Therapeutics’s revenue was up 115.4% compared to the same quarter last year. analysts expect that Juno Therapeutics will post -4.02 earnings per share for the current year.

In other news, EVP Robert Azelby sold 6,666 shares of Juno Therapeutics stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total transaction of $366,296.70. Following the sale, the executive vice president now owns 79,998 shares of the company’s stock, valued at approximately $4,395,890.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Sunil Agarwal sold 7,285 shares of Juno Therapeutics stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $44.76, for a total transaction of $326,076.60. The disclosure for this sale can be found here. Company insiders own 15.08% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Utah Retirement Systems raised its position in shares of Juno Therapeutics by 1.8% during the 2nd quarter. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company’s stock valued at $347,000 after buying an additional 200 shares during the period. State of Wisconsin Investment Board raised its position in shares of Juno Therapeutics by 1.7% during the 2nd quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 210 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Juno Therapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 228 shares during the period. Aperio Group LLC raised its position in shares of Juno Therapeutics by 4.2% during the 3rd quarter. Aperio Group LLC now owns 29,554 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 1,194 shares during the period. Finally, SG Americas Securities LLC raised its position in shares of Juno Therapeutics by 9.5% during the 3rd quarter. SG Americas Securities LLC now owns 15,254 shares of the biopharmaceutical company’s stock valued at $684,000 after buying an additional 1,328 shares during the period. 70.37% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Maxim Group Analysts Give Juno Therapeutics (JUNO) a $56.00 Price Target” was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.com-unik.info/2017/12/16/maxim-group-analysts-give-juno-therapeutics-juno-a-56-00-price-target.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

What are top analysts saying about Juno Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Juno Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit